Altintaş Ayse, Saruhan-Direskeneli Guher, Benbir Gulcin, Demir Mustafa, Purisa Sevim
Istanbul University Cerrahpasa School of Medicine, Department of Neurology, Istanbul, Turkey.
J Neurol Sci. 2009 Jan 15;276(1-2):41-4. doi: 10.1016/j.jns.2008.08.031. Epub 2008 Oct 9.
Osteopontin (OPN) was suggested to have a role in the pathophysiology of MS and in bone metabolism. However, we formerly reported increased presence of osteoporosis in MS patients independent of corticosteroid treatment, there is only limited information about the mechanism of bone loss. In this study, we investigated the role of OPN on bone mineral density in MS patients. Thirty-three relapsing-remitting (RR), 12 secondary progressive (SP), and 5 primary progressive (PP) MS patients and 30 healthy controls were prospectively enrolled. Students' t test, chi-square test, and Pearson correlations were used. The mean OPN level was 155.4+/-81.8 ng/ml in controls, and 15.9+/-36.2 ng/ml in MS patients (p<0.001).No statistical difference was observed among RR, SP and PPMS patients (p=0.162). No relationship was found between OPN levels and age at onset of disease (p=0.830), gender (p=0.785), MS subtypes (p=0.330), disease duration (p=0.744), or EDSS scores (p=0.633).About 34% of MS patients versus 10.3% of controls had osteoporosis (p=0.017).Osteopontin levels showed no significant correlation with osteoporosis in controls, but were lower in MS patients with osteoporosis in femur neck (r=0.85, p=0.010).The cumulative dose of corticosteroid treatment did not correlate with OPN levels (p=0.285).In conclusion, our results suggest that OPN may have a role as a shared cytokine in pathogenesis of MS and osteoporosis.
骨桥蛋白（OPN）被认为在多发性硬化症（MS）的病理生理学和骨代谢中发挥作用。然而，我们之前报道过，MS患者中骨质疏松症的发生率增加，且与皮质类固醇治疗无关，关于骨质流失机制的信息有限。在本研究中，我们调查了OPN在MS患者骨矿物质密度中的作用。前瞻性纳入了33例复发缓解型（RR）、12例继发进展型（SP）和5例原发进展型（PP）MS患者以及30名健康对照者。使用了学生t检验、卡方检验和Pearson相关性分析。对照组的平均OPN水平为155.4±81.8 ng/ml，MS患者为15.9±36.2 ng/ml（p<0.001）。RR、SP和PPMS患者之间未观察到统计学差异（p=0.162）。未发现OPN水平与疾病发病年龄（p=0.830）、性别（p=0.785）、MS亚型（p=0.330）、病程（p=0.744）或扩展残疾状态量表（EDSS）评分（p=0.633）之间存在关联。约34%的MS患者患有骨质疏松症，而对照组为10.3%（p=0.017）。对照组中OPN水平与骨质疏松症无显著相关性，但股骨颈患有骨质疏松症的MS患者中OPN水平较低（r=0.85，p=0.010）。皮质类固醇治疗的累积剂量与OPN水平无关（p=0.285）。总之，我们的结果表明，OPN可能作为一种共同的细胞因子在MS和骨质疏松症的发病机制中发挥作用。
